ERBB2 and breast carcinoma: Phase 2 clinical trials with FS-1502 are currently ongoing in various HER2‐positive solid tumor indications, including lung, gastric and colorectal cancer, and a randomized, controlled phase 3 trial comparing FS-1502 with T-DM1 is also being performed in HER2-positive advanced breast cancer.